The World Health Organization Quality of Life Scale Brief Version: a validation study in patiens with schizophrenia by Mas-Expósito, Laia et al.
The World Health Organization Quality of Life Scale Brief 
Version: A validation study in patients with schizophrenia 
Authors: Laia Mas-Expósito1,2, Juan Antonio Amador-Campos2,3, Juana Gómez-
Benito3,4, Lluís Lalucat-Jo1* for the Research Group on Severe Mental Disorder5.  
1. Department of Research, Centre d’Higiene Mental Les Corts, c/Numància 111-
115 baixos, 08029, Barcelona, Spain. Telephone number: 0034934198611. E-
mail: laia.mas@chmcorts.com 
2. Department of Personality, Assessment and Psychological Treatment, Faculty of 
Psychology, University of Barcelona, Passeig de la Vall d’Hebron 171, 08035, 
Barcelona, Spain. Telephone number: 0034933125131. E-mail: 
jamador@ub.edu 
3. Institute for Brain, Cognition and Behavior, Barcelona, Spain. 
4. Department of Methodology, Faculty of Psychology, University of Barcelona, 
Barcelona, Passeig de la Vall d’Hebron 171, 08035, Barcelona, Spain. 
Telephone number: 0034933125082. E-mail: juanagomez@ub.edu. 
5. The Work Group on Severe Mental Disorder is composed of the following 
members from Adult Mental Health Care Centers in Barcelona: Mª Antonia 
Argany, Francesca Asensio, Marta Berruezo, Carlos Blecua, Ignasi Bros, Ana 
Isabel Cerrillo, Ana del Cuerpo, Amparo Escudero, Judit Farré, Clara Fort, 
Marisa García, Mª Carmen González, Eva Leno, Lluís Mauri, Isabel Mitjà, 
Mónica Montoro, Montserrat Nicolás, Rosa Ordoñez, Carmen Pinedo, 
Montserrat Prats, Mª Joaquina Redin, Mª  Teresa Romero, Francesc Segarra, 
Juan Carlos Valdearcos, Immaculada Zafra, Matías Zamora y Antonio Zúñiga. 
 
*Corresponding author. Departament de Docència, Formació, Recerca i Publicacions, 
Centre d’Higiene Mental Les Corts, c/Numància 111-115 baixos, 08029, Barcelona, 
Spain. Tel.: +34 93 4391642. E-mail address: lluis.lalucat@chmcorts.com (L. Lalucat) 
 
Number of words in the manuscript: 3998 
Abstract 
Purpose: The World Health Organization Quality of Life Scale Brief Version 
(WHOQOL-BREF) is used for patients with schizophrenia although no validation is 
available. This work addresses this issue by dealing with its psychometric properties in 
a clinical sample of patients with schizophrenia. 
Methods: Two hundred forty-one patients from 10 Adult Mental Health Care Centers 
(AMHCC) meeting the following inclusion criteria were included: 1) International 
Classification of Diseases-10 or ICD-10 diagnosis of schizophrenia, 2) Global 
Assessment of Functioning scores or GAF≤50, 3) Illness duration of more than 2 years 
and 4) Clinical stability at assessment time. Patients were evaluated at baseline and at 
one-year follow-up regarding quality of life (QOL), clinical variables and other 
psychosocial measures. 
Results: Internal consistency was excellent for the total WHOQOL-BREF (0.88 at 
baseline and 0.89 at follow-up) and adequate (0.65 to 0.78 at baseline; 0.66 to 0.79 at 
one-year follow-up) for the WHOQOL-BREF domains. Correlations between 
WHOQOL-BREF scores and those of global functioning, psychiatric symptoms, 
disability and social support ranged between small and large. There were significant 
differences between groups of patients with schizophrenia in the WHOQOL-BREF. 
Patients who were anxious, disabled, lacked social support and used more social 
services scored significantly lower in some or all WHOQOL-BREF domains. Changes 
in WHOQOL-BREF scores were positively associated with changes over time in global 
functioning, social support and use of health services, and negatively with psychiatric 
symptoms and disability (correlation coefficients between small and moderate). After 
one-year follow-up, patients improved in overall functioning and there was a decrease 
in psychiatric symptoms.  
Conclusions: This study shows that the WHOQOL-BREF has good reliability and 
validity, and suggests that it is suitable for the assessment of QOL in patients with 
schizophrenia. 
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The World Health Organization Quality of Life Scale Brief 
Version: A validation study in patients with schizophrenia 
1. Introduction 
Quality of life (QOL) in patients with schizophrenia is an area of increasing significance 
because it is an essential component for clinical trials and patient management. The 
assessment of QOL takes into account patients’ rights, autonomy and opinions during 
the processes involving diagnosis and care[1]. Although it is not clear whether patients 
with schizophrenia are good at evaluating their QOL because they might show cognitive 
and insight deficits, there is evidence that support the validity of the assessment made 
by these patients[2].  
Valid and reliable instruments to assess QOL have been developed for use with various 
target populations. Those instruments are grouped into specific and generic[3]. Specific 
instruments aim to assess QOL in particular target populations, while generic 
instruments aim to assess QOL across a variety of disease indications as well as healthy 
population. These types of instruments are complementary and wherever possible it is 
preferable to use them together.  The Quality of Life Scale[4], the Quality of Life 
Interview[5] or the Lancashire Quality of Life Profile[6] are specific instruments for 
patients with schizophrenia. The World Health Organization Quality of Life Scale[7] or 
WHOQOL-100, the 36-Item Short Form Survey[8] and the EUROQOL instrument[9] 
are generic instruments.  
The World Health Organization Quality of Life Scale Brief Version[10] or WHOQOL-
BREF is  a short version of the WHOQOL-100[7] and it was developed to deal with 
time restrictions, minimize respondent burden and for use in situations where facet-level 
detail is unnecessary[11]. Both scales support a characterization of QOL defined as 
“individuals' perceptions of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards and 
concerns[12]” (p.28). They allow a comprehensive assessment of QOL and can be used 
in different settings such as medical practice, research or audit. The WHOQOL-BREF is 
an international cross-culturally analogous QOL evaluation tool[13] which contains 
aspects regarding social relations and environment not covered by other instruments.  
The WHOQOL-BREF has been adapted and validated in the general population[14-17], 
adolescents[18], older people[19-21], smokers[22], alcoholics[23], patients with 
HIV/AIDS[24], traumatic injuries[25;26] and psychiatric outpatients[27-29]. 
The suitability of the scale, the aspects it covers, its reliability and validity in other 
populations makes it promising for the assessment of patients with schizophrenia[30-
34] although no validation is available. This work addresses this issue by validating this 
instrument in a sample of patients with schizophrenia. Firstly, we aim to establish its 
overall internal consistency and the internal consistency associated with its domains. 
Secondly, we address WHOQOL-BREF validity evidence: associations with clinical 
and psychosocial variables, and QOL differences between groups of patients with 
schizophrenia, established according to socio-demographic variables, psychiatric 
symptoms, disability, social support and use of health services. The association between 
subjective QOL and socio-demographic variables is controversial and it is currently 
considered that socio-demographic variables are not significantly associated with 
QOL[35-37]. We do not expect significant differences in QOL between groups of 
patients established according to socio-demographic variables. It is thought that 
perceived social support has a positive relationship with subjective QOL, while 
disability, the severity of depression, anxiety and negative symptoms as well as use of 
services have a negative one[38]. Consequently, we expect that disabled, depressed and 
anxious patients, as well as those lacking social support and those with higher health 
service use show poorer levels of subjective QOL. Finally, we aim to test changes in 
QOL, along with other variables, after one-year follow-up. As a result of the treatment 
provided to patients, we expect significant improvements in global functioning, 
psychiatric symptoms, disability, social support and QOL. 
 
 
 
 
 
 
2. Method 
2.1. Sample 
Patients came from 10 Adult Mental Health Care Centers (AMHCC) in Barcelona 
(Spain). These AMHCC are run by the Catalan Department of Health and share similar 
characteristics regarding the care provided to patients. They offer a care package to 
patients with schizophrenia by means of multidisciplinary community mental health 
teams (i.e. a psychiatrist, a psychologist, a community mental health nurse and a social 
worker). This care package involves medical and psychosocial interventions of varying 
intensity depending on patients’ needs and is coordinated by one of the members of the 
mental health teams (i.e. a community mental health nurse).  
From December 2006 to January 2008, these AMHCC participated in a study consisting 
of a one-year follow-up of patients in contact with services who met the following 
inclusion criteria: 1) Global Assessment of Functioning or GAF[39] scores of 50 or 
lower, 2) Illness length greater than 2 years, 3) International Classification of Diseases-
10 or ICD-10[40] diagnosis of schizophrenia and 4) Clinical stability at assessment 
time. Patients were excluded if they had dementia, organic brain injury or mental 
retardation. Patients who visited consecutively and who met study inclusion criteria 
were asked to participate. Specifically, 260 patients met these inclusion criteria but 19 
did not consent to participate. Data from this study was used for the present work. 
The final sample comprised 241 (67.6% male) patients, their mean age was 41.7 years 
(SD = 11.6) and 72.6% of them had illness duration greater than 10 years; 70.5% of 
patients had a diagnosis of paranoid schizophrenia and 29.5% of other schizophrenias 
(i.e. 10.8% undifferentiated, 9.1% residual, 6.2% hebephrenic, 1.2% simple and 2.1% 
other). Other socio-demographic characteristics of patients are described in Table 1.  
INSERT ABOUT HERE TABLE 1 
A total of 219 patients (90.9%) were successfully evaluated at one-year follow-up. 
Sixteen people (out of 22) were not evaluated following their psychiatrist’s instructions 
because they were not clinically stable at assessment time or did not have contact with 
services, 3 died (1 from terminal illness and 2 by suicide), 2 did not properly complete 
the evaluation and 1 dropped out of the study. 
2.2. Instrument 
The WHOQOL-BREF is composed of 26 items taken from the 100 items in the 
WHOQOL-100. It contains one item for each of the 24 facets included in the 
WHOQOL-100 and two items (not considered in the scoring) regarding overall QOL 
and general health. It requires 10 minutes to administer and assesses subjective QOL in 
four domains: 1) Physical Health (PH; e.g. “How satisfied are you with your sleep?”; 
theoretical range: 7-35), 2) Psychological (P; e.g. “How much do you enjoy life?”; 
theoretical range: 6-30), 3) Social Relationships (SR; e.g. “How satisfied are you with 
your personal relationships?”; theoretical range: 3-15) and 4) Environment (E; e.g. 
“How satisfied are you with your access to health services?”; theoretical range: 8-40), 
and provides an overall QOL measure (theoretical range: 26-130). Each item is rated on 
a five-point Likert Scale, ranging from 1 (Not at all, Very dissatisfied, Very poor) to 5 
(An extreme amount, Very satisfied, Very good). The higher the score, the better the 
QOL reported by the patient except for items 3, 4 and 26 that, therefore, need to be 
reversed for the scoring.  
The development of the WHOQOL-BREF involved: 1) review of QOL cultural 
concepts, 2) definition of WHOQOL-BREF domains and 3) development and 
translation of WHOQOL-BREF questions [41]. The WHOQOL-BREF showed good 
psychometric properties. Internal consistency values ranged from 0.66 to 0.84; and 
correlations with the WHOQOL-100 subscales ranged from 0.89 to 0.95. Skevington et 
al.[42] confirmed and extended information about its properties and showed good to 
excellent psychometric properties in adults recruited from in-patient and outpatient 
health care facilities, regardless of diagnosis or severity, and from the general 
population. 
2.3. Procedure 
The study was approved by the Ethics Committee of the Catalan Union of Hospitals in 
accordance with the ethical standards of the 1964 Declaration of Helsinki. The 
procedures and assessments were described to each patient who then provided informed 
consent.  
The community mental health teams performed patients’ assessments. The diagnosis 
was established by the psychiatrist by means of a non-structured interview following 
ICD-10[40] research diagnosis criteria and considered self-reports and caregiver reports. 
The psychiatrist also carried out the assessment of psychiatric symptoms, while the rest 
of the assessments were performed by the other members of the community mental 
health teams under the psychiatrist’s supervision. The psychiatrist was in charge of 
setting up the assessment agenda, supervising its development and sending the sheet 
scores to the psychologist in charge of the design and analyses of the study database. 
To ensure the quality of assessment data, all psychiatrists participated in a schizophrenia 
diagnostic agreement workshop comprising two case studies. All researchers were 
trained in the administration of the instruments in a 4-hour session run by a psychologist 
with experience in psychological assessment of psychiatric patients. Systematic reviews 
of data coding and registration were taken and patient information was contrasted with 
data from the AMHCC responsible for each patient. 
Patients were evaluated at baseline and at one-year follow-up with the following 
assessment tools:  
The WHOQOL-BREF[43]. 
The GAF[39]. This is a reliable and valid measure of global psychological functioning 
in patients with severe mental disorder. Its theoretical range is 1–100, where 100 
denotes best possible functioning.  It is included in the Diagnostic and Statistical 
Manual of Mental Disorders Fourth Edition [39] or DSM-IV. 
The Positive and Negative Syndrome Scale or PANSS[44]. This instrument is used for 
assessing symptom severity in patients with schizophrenia and it is translated and 
validated in Spanish[45]. It assesses psychiatric symptoms in three domains: positive 
(theoretical range: 7-49 where 49 denotes higher levels of positive psychiatric 
symptoms), negative (theoretical range: 7-49 where 49 represents higher levels of 
negative psychiatric symptoms), general (theoretical range: 16-112; where 112 denotes 
higher levels of general psychiatric symptoms), and provides an overall measure of 
psychiatric symptoms (theoretical range: 30-210, where 210 means higher levels of 
psychiatric symptoms). Internal consistency values of its subscales range between 
medium and high and its convergent validity with other measures of psychiatric 
symptoms is high and range from 0.70 to 0.81[45]. 
The World Health Organization Short Disability Assessment Schedule or DAS-s[46]. 
This is a seven-item scale developed by the World Health Organization and its 
theoretical range is between 0 and 30, where 30 corresponds to higher levels of 
disability. It is a valid measure of global functioning in patients with mental disorders 
included in the ICD-10[40]. 
The Functional Social Support Questionnaire or FSSQ[47]. This is an eight-item 
questionnaire that measures the strength of the patient’s social network. It assesses 
perceived social support in two domains: confidential social support (theoretical range: 
6-30, where 30 denotes higher levels of confidential social support) and affective social 
support (theoretical range: 5-25, where 25 represents higher levels of affective social 
support), and provides an overall measure of social support (theoretical range: 11-55, 
where 55 shows higher levels of social support). It is also translated and validated in 
Spanish[48] and the reliability indexes are of 0.80 and 0.92 for hetero-report and self-
report, respectively. The concurrent validity with other health measures ranges from 
0.20 to 0.21 and from -0.13 to -0.81[48]. 
First, the psychiatrist conducted the assessment of global functioning and psychiatric 
symptoms with the GAF and the PANSS to check if patients meet inclusion criteria. 
Then, the other members of the community mental health teams administered the rest of 
assessment tools in the following order: 1) DAS-s, 2) the WHOQOL-BREF and 3) the 
FSSQ.  
After each evaluation, systematic reviews of data coding and registration were taken 
and patient information was contrasted with family interviews and AMHCC registered 
data. 
2.4. Data analysis 
Data were analyzed using the Statistical Package for the Social Sciences v.15.  
Internal consistency was evaluated by means of Cronbach’s α and the contribution of 
WHOQOL-BREF items to the overall α, and the α associated with their domains. The 
internal consistency was calculated at baseline and at one-year follow-up. Cronbach’s α 
values were considered as follows: 0.60≤ α <0.80 adequate, 0.80≤ α <0.85 good and α 
≥0.85 excellent[49]. 
To assess validity evidence[50], Pearson’s correlations between WHOQOL-BREF 
scores at baseline and the GAF, PANSS, DAS-s and FSSQ scores at baseline were 
calculated. Correlation values were considered as follows: 1) <0.3 = small, 2) 0.3 to 0.5 
= moderate and 3) ≥5 large[51]. T-tests and analysis of variance were used to analyze 
differences in WHOQOL-BREF scores between groups of patients with schizophrenia.  
Patient groups were defined according to socio-demographic variables, the presence of 
anxiety symptoms[44] (item 2 of PANSS general ≥4), depressive symptoms[44] (item 6 
of  PANSS general ≥4), lack of social support[48] (FSSQ ≤32) and disability (DAS-s 
total mean score ≥4). For the DAS-s a cut-off score of ≥4 was considered because an 
item score ≥4 indicates the presence of disability even with assistance[46]. Moreover, 
patients groups were defined according to use of health services during the year prior to 
baseline assessment.  
T-tests for dependent samples were used to assess change over time between baseline 
and at one-year follow-up for WHOQOL-BREF, GAF, PANSS, DAS-s and FSSQ 
scores, and use of community mental health services (i.e. community psychiatric visits 
and community nursing visits). We compared the number of patient visits during the 
year prior to baseline assessment and the number of patient visits during the year 
following this assessment. The Bonferroni correction for multiple comparisons was 
applied[52] and a p value ≤0.003 was considered significant. The effect size was also 
estimated[53] and its values were considered as follows: 1) <0.3=small, 2) 0.3 to 
0.5=moderate and 3) ≥5 large[51]. 
Differences between scores at baseline and at one-year follow-up were calculated for 
WHOQOL-BREF scores, GAF, PANSS, DAS-s, FSSQ scores and use of community 
services. Sensitivity to change was determined by Pearson’s correlation coefficients 
between WHOQOL-BREF score differences and the other score differences. 
 
3. Results 
3.1. Internal consistency 
Internal consistency coefficients at baseline for WHOQOL-BREF total score was 0.88 
and 0.89 at one-year follow-up. For the WHOQOL-BREF domains, coefficients ranged 
between 0.65 and 0.78 at baseline and between 0.66 and 0.79 at one-year follow-up.  
We also tested the change in Cronbach's alpha values when items are suppressed. Only 
the suppression of item 4 (i.e. “How much do you need any medical treatment to 
function in your daily life?”) increased the level of internal consistency of the total 
WHOQOL-BREF by 0.01, at baseline and at one-year follow-up. The suppression of 
any other items maintained or decreased internal consistency coefficients by 0.01 at 
baseline and at one-year follow-up. Similar results have been reported regarding the 
WHOQOL-BREF domains. Specifically, item suppression increases or decreases 
Cronbach's alpha values by 0.01, which may be considered negligible. 
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3.2. Validity evidence 
Pearson's correlations between WHOQOL-BREF scores and GAF, PANSS, DAS-s and 
FSSQ scores at baseline were mostly significant, and ranged from -0.04 to 0.55 (see 
Table 2). Specifically, correlations between WHOQOL-BREF and GAF scores were 
small; correlations between WHOQOL-BREF and PANSS scores were negative and 
small; correlations between WHOQOL-BREF and DAS-s scores were also negative but 
moderate, and correlations between WHOQOL-BREF and FSSQ scores ranged between 
small and large. 
Table 2 shows the differences in groups of patients with schizophrenia in WHOQOL-
BREF scores. There were no statistically significant differences in WHOQOL-BREF 
scores between groups established according to socio-demographic variables. There 
were significant differences between groups of patients with schizophrenia based on 
psychiatric symptoms, social functioning and use of health services. In particular, there 
were significant differences between anxious and non-anxious patients in WHOQOL-
PH and WHOQOL-P. Anxious patients scored significantly lower in those domains.  
Disabled patients and patients without social support scored significantly lower in 
almost all WHOQOL-BREF domains.  
Regarding social health service use, there were significant differences between groups 
in WHOQOL-E. Patients that used those services scored lower in this domain than 
those patients that did not use those services. No other differences were observed 
regarding use of health services. 
3.3. Changes over time 
There were statistically significant changes over time regarding PANSS positive, 
PANSS negative, PANSS general, PANSS total, GAF clinical and GAF social scores. 
To be precise, there was a decrease in psychiatric symptoms as shown by change in 
PANSS scores over time and an improvement in overall functioning as indicated by 
changes in GAF scores over time. Effect sizes were medium for most scores but small 
for GAF social scores. DAS-s scores decreased over time but not significantly and 
WHOQOL-BREF scores and FSSQ scores remained about the same over time. With 
regard to use of health services, there were statistically significant changes over time in 
community nursing visits. Specifically, there was an increase in community nursing 
visits with a small effect size. No other statistically significant differences over time 
were observed (See Table 3). 
INSERT ABOUT HERE TABLE 3 
3.4. Sensitivity to change 
Firstly, score differences between baseline and one-year follow-up were calculated for 
WHOQOL-BREF domains, WHOQOL-BREF total score, the other assessment tools 
and community service visits. Secondly, Pearson's correlation coefficients between 
WHOQOL-BREF score differences and all other score differences were calculated. 
Table 4 shows that Pearson's correlations between changes in WHOQOL-BREF scores 
and changes in GAF, PANSS, DAS-s, FSSQ scores and community service visits were 
mostly significant. Those coefficients ranged from -0.00 to 0.36. In particular, 
correlations between the change in WHOQOL-BREF and the change in GAF scores 
were small; correlations between changes in WHOQOL-BREF and changes in PANSS 
and DAS-s scores were negative and small; correlations between changes in 
WHOQOL-BREF and changes in FSSQ scores ranged between small and moderate. As 
for use of health services, only community nursing visits showed statistically significant 
correlations. Specifically, correlations between changes in WHOQOL-BREF scores and 
changes in community nursing visits were small.  
INSERT ABOUT HERE TABLE 4 
 
4. Discussion  
The aim of this study was to validate the WHOQOL-BREF in patients with 
schizophrenia. The WHOQOL-BREF showed suitable psychometric properties in this 
patient population. 
Internal consistency values at baseline and at one-year follow-up were excellent for the 
total WHOQOL-BREF and adequate for WHOQOL-BREF domains. These findings are 
in agreement with the evidence about the psychometric properties of the WHOQOL-
BREF. During the development of the WHOQOL-BREF[41], Cronbach’s α values of 
the WHOQOL-BREF domains ranged between 0.66 and 0.84. In 2002, the WHOQOL 
group participated in a field trial held in 23 countries, which intended to confirm and 
extend information on WHOQOL-BREF psychometric properties. Cronbach’s α values 
of the WHOQOL-BREF domains observed ranged between 0.55 and 0.88 for the PH 
domain, between 0.73 and 0.89 for the P domain, between 0.55 and 0.77 for the SR 
domain and between 0.65 and 0.87 for the E domain[42]. In a study with adult 
psychiatric outpatients, the internal consistency of the WHOQOL-BREF four domains 
ranged from 0.66 to 0.80[29]. 
We expected to find that global functioning and perceived social support had a positive 
relationship with subjective QOL, while the severity of depression, anxiety and negative 
symptoms as well as disability and use of services had a negative one[38]. Those were 
the directional relationships of the present findings, which also have been found in other 
studies. Some authors have found similar associations between the domains of the 
WHOQOL-BREF and measures of psychopathological symptoms, social 
support[24;29] and functioning[54]. One should note that the correlation coefficients of 
QOL with those variables ranged between small and large, with disability and social 
support showing the largest coefficients. This might suggest that disability and social 
support are more closely related to QOL than psychiatric symptoms and global 
functioning. However, it should be emphasized that psychiatric symptoms and 
functioning were assessed by clinicians, while QOL and social support were self-rated 
by patients. Those results suggest that patients’ perceptions of mental health do not 
correspond with clinicians’ perceptions[55-57]. Some authors have even argued that 
those perceptions might be independent[58-60]. This lack of agreement between 
informants might be related to higher associations between measures provided by the 
same informant than between measures provided by different informants[61]. 
There were no differences in WHOQOL-BREF domains between groups of patients 
established according to socio-demographic variables. The present findings have been 
observed in other studies. Skantze et al.[62] showed that QOL had no association with 
gender, marital status and standard of living, while in a multicentre study[63] no 
differences in subjective QOL between men and women with schizophrenia were 
observed. Young[64] found no associations between perceived QOL and sex, age, 
education and marital status. Although some studies have reported significant 
associations between subjective QOL and socio-demographic factors[29; 55; 65], it is 
agreed that the relationship between socio-demographic factors and subjective QOL is 
controversial, weak, or non-existent[38]. Therefore, socio-demographic variables are 
still not considered to be significantly associated with QOL in patients with 
schizophrenia, which is consistent with our results. 
There were significant differences between patient groups. Disabled patients and 
patients lacking social support showed poorer levels of QOL in almost all WHOQOL-
BREF domains, while anxious patients scored lower in the PH and P domains of the 
WHOQOL-BREF. Although one should note that group differences may be unreliable 
since they were made according to established cut-offs of single scale items rather than 
through diagnostic interviews, our results are consistent with findings which show that 
QOL is associated with disability, social support and psychiatric symptoms[30]. 
Patients who used social services more showed poorer levels of QOL related to 
environment. In other words, patients with more care needs at a social level appeared to 
show poorer levels of QOL. The association between care needs and QOL in patients 
with schizophrenia has been widely investigated[38] and it has been shown that there is 
a relationship between high numbers of unmet needs and low QOL, which is consistent 
with the present findings. 
There are differences in QOL when comparing patients with schizophrenia with healthy 
subjects or other clinical groups[38]. Patients with schizophrenia are significantly 
impaired in both the general and all specific QOL domains compared with healthy 
subjects but only in some domains when compared with other clinical groups. At 
baseline, WHOQOL-BREF scores in our study sample differed from those of healthy 
people. For example, in the development of the WHOQOL-BREF[41] mean scores in 
healthy people were 16.2 for the PH, 15 for the P, 14.3 for the S and 13.5 for the E 
domain, which were higher than those in our sample. Akvardar et al.[66] showed 
similar WHOQOL-BREF scores to those obtained in our study and found that patients 
with schizophrenia scored significantly lower than healthy subjects in all WHOQOL-
BREF domains. They also showed lower scores in the P and SR domains when 
compared to patients with diabetes and bipolar disorder. 
At one-year follow-up, we expected, as a consequence of the role of AMHCC in the 
provision of care to patients with schizophrenia, a decrease in levels of psychiatric 
symptoms and disability and an increase in levels of global functioning, QOL and social 
support. There were only improvements regarding psychiatric symptoms and global 
functioning together with an increase of community psychiatric nursing visits. We 
observed a decrease in disability but non-significant and we did not observe 
improvements regarding QOL and social support as perceived by patients. Although 
WHOQOL-BREF was sensitive to changes over time, the associations between changes 
in WHOQOL-BREF scores and changes in the rest of variables were mostly small 
except for changes in social support that ranged between small and moderate. Again, 
those results might show lack of agreement between patients’ and clinicians’ 
assessments. Moreover, the lack of improvements regarding QOL could be explained by 
the fact that impairment in QOL appears to be relatively stable across the course of the 
illness[38]. 
To date, the WHOQOL-BREF has been used for the assessment of patients with 
schizophrenia although no validation of the scale is available. The present findings 
provide evidence regarding the psychometric properties of the WHOQOL-BREF in 
patients with schizophrenia, which supports its use in this patient population. It shows 
that the WHOQOL-BREF has good reliability and validity, and suggests that it is a 
suitable scale for the assessment of QOL in patients with schizophrenia. Taking all the 
above into account, the WHOQOL-BREF could be used in patients with schizophrenia 
as an assessment tool for purposes such as research or routine practice. 
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Table 1. Socio-demographic characteristics of the sample at baseline 
 
Variable N % 
Age*     
  ≤ 42 years 133 42.8 
  > 42 years 178 57.2 
Gender   
  Females 78 32.4 
  Males 163 67.6 
Illness duration   
  ≤ 10 years 66 27.4 
  > 10 years 175 72.6 
Marital status   
  Single 181 75.1 
  Living with partner or married 32 13.3 
  Divorced or separated or widow 28 11.6 
Educational level   
   ≤ Primary school 113 46.9 
   >Primary school 128 53.1 
Living arrangement   
   Family Property 166 68.9 
   Others 45 31.1 
Employment status   
   Active 53 22 
   Non-active 188 78 
Schizophrenia type   
  Paranoid 170 70.5 
   Other 71 29.5 
 
*The two groups have been established taking into account the mean  
Table 2. Validity evidence of the WHOQOL-BREF1 for patients with schizophrenia 
 WHOQOL 
PHYSICAL 
WHOQOL 
PSYCHOLOGICAL 
WHOQOL 
SOCIAL RELATIONS 
WHOQOL 
ENVIRONMENT 
WHOQOL 
TOTAL 
Association with clinical and psychosocial variables: [r (p 
value)] (n=241) 
GAF2-clinical 
GAF-social 
PANSS3 positive 
PANSS negative 
PANSS general 
PANSS total 
DAS-s4 
FSSQ5-total social support 
FSSQ-confidential support 
FSSQ-affective support 
 
 
 0.17 (p=0.010) 
 0.20 (p=0.002) 
ns 
ns 
-0.17 (p=0.008) 
-0.13 (p=0.038) 
-0.30 (p<0.001) 
 0.35 (p<0.001) 
 0.34 (p<0.001) 
 0.25 (p<0.001) 
 
 
0.25 (p<0.001) 
0.20 (p=0.002) 
-0.18 (p=0.005) 
ns 
-0.25 (p<0.001) 
-0.21 (p=0.001) 
-0.31 (p<0.001) 
0.35 (p<0.001) 
0.34 (p<0.001) 
0.29 (p<0.001) 
 
 
ns 
ns 
-0.13 (p=0.048) 
-0.14 (p=0.033) 
-0.19 (p=0.004) 
-0.18 (p=0.004) 
-0.31 (p<0.001) 
0.55 (p<0.001) 
0.53 (p<0.001) 
0.41 (p<0.001) 
 
 
0.21 (p=0.001) 
0.23 (p<0.001) 
-0.14 (p=0.025) 
ns 
-0.19 (p=0.002) 
-0.17(p=0.008) 
-0.36 (p<0.001) 
0.51 (p<0.001) 
0.49 (p<0.001) 
0.40 (p<0.001) 
 
 
0.23 (p<0.001) 
0.23(p<0.001) 
-0.17 (p=0.009) 
ns 
-0.24 (p<0.001) 
-0.21 (p=0.001) 
-0.40 (p<0.001) 
0.52 (p<0.001) 
0.50 (p<0.001) 
0.42 (p<0.001) 
Group differences: [t test(p value)] (n=241) 
Age (≤42years old:>42 years old) 
Gender (male: female) 
Illness length (≤10 years:>10 years) 
Education (≤ primary school: >primary school) 
Employment status (active: non active) 
Diagnosis (paranoid schizophrenia: other schizophrenias) 
Living arrangement  (family property: others) 
[F (p value)] 
Marital status (single: married or living with partner: divorced 
or separated or widow) 
[t test (p value)] 
 
ns 
ns 
ns 
ns 
ns 
ns 
 
ns 
 
ns 
 
ns 
ns 
ns 
ns 
ns 
ns 
 
ns 
 
ns 
 
 
ns 
ns 
ns 
ns 
ns 
ns 
 
ns 
 
ns 
 
 
ns 
ns 
ns 
ns 
ns 
ns 
 
ns 
 
ns 
 
ns 
ns 
ns 
ns 
ns 
ns 
 
ns 
 
ns 
 
Depressed vs. non depressed (PANSS general: item number 6 ≥ 
4 vs. item number 6 < 4) 
Anxious vs. no anxious (PANSS general: item number 2 ≥ 4 vs. 
item number 2 < 4) 
Disabled vs. non disabled  
(DAS-s ≥ 4 vs. DAS-s<4) 
Lacking social support vs. having social support 
(FSSQ ≤ 32 vs. FSSQ > 32) 
Use of social services vs. no use of social servicesϒ  
Use of emergency calls vs. no use of emergency callsϒ 
ns 
 
 3.23 (p=0.001) 
 
ns 
 
-4.45 (p<0.001) 
 
ns 
ns 
ns 
 
3.76 (p<0.001) 
 
3.14 (p=0.001) 
 
-4.28 (p<0.001) 
 
ns 
ns 
ns 
 
ns 
 
2.72 (p=0.003) 
 
-7.37 (p<0.001) 
 
ns 
ns 
ns 
 
ns 
 
4.30 (p<0.001) 
 
-6.62 (p<0.001) 
 
-2.96 (p=0.003) 
ns 
ns 
 
ns 
 
3.92 (p<0.001) 
 
-6.94 (p<0.001) 
 
ns 
ns 
n= simple size at baseline; ns: non-significant; ϒ: Time frame : patient visits during the year previous to the fist assessment versus patients visits during a year after the first assessment 
1.WHOQOL-BREF: World Health Organization Quality of Life Brief Version; 2. GAF: Global Assessment of Functioning;  3. PANSS: Positive and Negative Syndrome Scale; 4. DAS-s: The World Health 
Organization Short Disability Assessment Schedule; 5. FSSQ: Functional Social Support Questionnaire 
Table 3. Clinical and psychosocial variables and use of health services at baseline and at one year follow-up 
 
Measure Baseline 1 year follow-up Differences over time 
 Mean SD Mean SD t p ES 
(n=219) 
PANSS1 positive 
 
16.67 
 
6.26 
 
15.22 
 
6.10 
 
5.02 
 
<0.001 
 
0.32 
PANSS  negative 24.07 6.99 22.34 6.90 5.08 <0.001 0.33 
PANSS  general 42.35 12.73 39.22 12.30 5.30 <0.001 0.34 
PANSS  total 83.10 22.47 76.79 21.96 6.14 <0.001 0.38 
GAF2 clinic 47.07 9.69 49.58 11.01 -4.94 <0.001 0.32 
GAF social 44.29 10.00 46.26 10.36 -3.45 <0.001 0.23 
DAS-s3 9.09 4.46 8.59 4.46 2.37 ns 0.16 
WHOQOL-BREF4 physical health 13.25 2.42 13.27 2.54 -0.95 ns 0.01 
WHOQOL-BREF psychological health 12.18 2.86 12.19 2.81 -0.01 ns 0.00 
WHOQOL-BREF social relationships 10.54 3.26 10.50 3.24 0.23 ns 0.02 
WHOQOL-BREF environment 13.24 2.26 13.31 2.36 -0.51 ns 0.04 
WHOQOL-BREF general 81.82 13.94 81.95 14.11 -0.18 ns 0.01 
FSSQ5 total social support 36.68 9.47 36.57 9.72 0.22 ns 0.02 
FSSQ  confidant support 16.55 4.99 16.37 5.17 0.63 ns 0.00 
FSSQ  affective support 10.90 3.14 10.78 3.22 0.68 ns 0.00 
Community psychiatric visitsϒ 5.76 4.22 6.28 4.43 -1.75 ns 0.12 
Community nursing visitsϒ 5.92 7.13 8.38 9.03 -4.35 <0.001 0.28 
SD: standard deviation; ns: non-significant ; ϒ. Time frame: patient visits during the year previous to the fist assessment versus patients visits during a year after the first assessment 
 
1. PANSS: Positive and Negative Syndrome Scale; 2. GAF: Global Assessment of Functioning; 3. DAS-s: The World Health Organization Short Disability Assessment Schedule; 4. WHOQOL-
BREF: World Health Organization-Quality of Life Scale Brief Version; and 5. FSSQ: Functional Social Support Questionnaire 
 
 
 
 
Table 4. Sensitivity to change of the WHOQOL-BREF1 for patients with schizophrenia 
 WHOQOL 
PHYSICAL  
r(p) 
WHOQOL 
PSYCHOLOGICAL  
r(p) 
WHOQOL 
SOCIAL RELATIONS 
r(p) 
WHOQOL 
ENVIRONMENT 
r(p) 
WHOQOL 
TOTAL 
r(p) 
Sensitivity to change (n= 219) 
GAF2 clinical 
GAF social 
PANSS3 positive 
PANSS negative 
PANSS general 
PANSS total 
DAS-s4 
FSSQ5 total social support 
FSSQ confidential support 
FSSQ affective support 
Nursing community visits (n=218)ϒ 
Psychiatric community visits (n=218)ϒ 
 
0.11 (p=0.092) 
0.23 (p=0.001) 
-0.10 (p=0.132) 
-0.16 (p=0.017) 
-0.14 (p=0.038) 
-0.16 (p=0.016) 
-0.15 (p=0.030) 
0.24 (p<0.001) 
0.25 (p<0.001) 
0.17 (p=0.014) 
0.12 (p=0.075) 
0.03 (p=0.699) 
 
0.14 (p=0.035) 
0.18 (p=0.008) 
-0.10 (p=0.145) 
-0.19 (p=0.005) 
-0.19 (p=0.004) 
-0.20 (p=0.003) 
-0.19 (p=0.006) 
0.27 (p<0.001) 
0.27 (p<0.001) 
0.21 (p=0.002) 
0.09 (p=0.190) 
0.01 (p=0.888) 
 
0.09 (p=0.198) 
0.07 (p=0.283) 
-0.15 (p=0.029) 
-0.16 (p=0.019) 
-0.20 (p=0.003) 
-0.21 (p=0.002) 
-0.16 (p=0.020) 
0.28 (p<0.001) 
0.31 (p<0.001) 
0.07 (p=0.299) 
0.18 (p=0.007) 
-0.06 (p=0.392) 
 
0.04 (p=0.539) 
0.14 (0=0.035) 
-0.02 (p=0.803) 
-0.08 (p=0.236) 
-0.05 (p=0.448) 
-0.06 (p=0.368) 
-0.11 (p=0.112) 
0.27 (p<0.001) 
0.26 (p<0.001) 
0.21 (p=0.002) 
0.01 (p=0.892) 
0.00 (p=0.989) 
 
0.14 (p=0.035) 
0.23 (p=0.001) 
-0.13 (p=0.065) 
-0.20 (p=0.003) 
-0.19 (p=0.004) 
-0.21 (p=0.001) 
-0.21 (p=0.001) 
0.36 (p<0.001) 
0.36 (p<0.001) 
0.25 (p<0.001) 
0.11 (p=0.096) 
0.00 (p=0.947) 
n = sample size; ϒ: Time frame: patient visits during the year previous after first assessment vs. patient visits during the year after the second assessment. 
1.WHOQOL-BREF: World Health Organization Quality of Life Scale Brief Version; 2. GAF: Global Assessment of Functioning;  3. PANSS: Positive and Negative Syndrome Scale; 4. DAS-s: 
The World Health Organization Short Disability Assessment Schedule; 5. FSSQ: Functional Social Support Questionnaire 
 
 
 
 
